AstraZeneca CEO Pascal Soriot announced a sweeping plan to invest $50 billion in the United States through 2030, including a $4 billion new drug manufacturing site in Virginia. The initiative involves broad expansion of manufacturing and research facilities across multiple states, including Massachusetts, Maryland, Indiana, and Texas. AstraZeneca aims to generate half of its anticipated $80 billion annual revenue from the U.S. market by then, with most of its new product pipeline originating domestically. This effort to bolster onshore drug production aligns with national security concerns and shifts in trade policies, reflecting a strategic pivot toward American biotech and pharmaceutical leadership.